All AbMole products are for research use only, cannot be used for human consumption.
Clinofibrate is a new hypelipidemic agent and a competitive hydroxymethylglutaryl coenzyme A reductase with an IC50 of 0.47 mM. Clinofibrate is a derivative of clofibrate. Clinofibrate, as a antihyperlipidemic drug, activiates human liver 3alpha-hydroxysteroid dehydrogenase. The optimal pha of activation this enzyme by the compound clinofibrate was about 7.5. The concentrations giving maximum stimulation (1.8 to 2.4 fold) for clinofibrate were 50 μM. The activation by the antihyperlipidemic drug, clinofibrate, elevated both Km and Kcat (turnover number) values for the coenzyme and substrates. Clinofibrate lacks the chloro group, methyl goup on the alpha-carbon or carboxyl group. Thus, clinofibrate greatly decreased the stimulatory effects. Kinetic analysis with respect to NAPD+ exhibited that clinofibrate was nonessential activators with dissociation constants of 6 μM. These data suggest that the long-term treatment with the antihyperlipidemic drugs generates effects on the metabolism of steroid hormones and bile acids, as well as several-containing drugs mediated by the enzyme.
| Cell Experiment | |
|---|---|
| Cell lines | |
| Preparation method | |
| Concentrations | |
| Incubation time | |
| Animal Experiment | |
|---|---|
| Animal models | Seven-week-old Sprague-Dawley rats (SLC), six-week-old ICR-SLC mice and a one-year-old beagle dog |
| Formulation | |
| Dosages | 30 mg/kg |
| Administration | Administered orally or intravenously |
| Molecular Weight | 468.58 |
| Formula | C28H36O6 |
| CAS Number | 30299-08-2 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Yohtaro Sato, et al. Clinofibrate improved canine lipid metabolism in some but not all breeds
| Related HMG-CoA Reductase Products |
|---|
| Mevastatin
Mevastatin is a competitive inhibitor of HMG-Coenzyme A (HMG-CoA) reductase with a binding affinity 10,000 times greater than the HMG-CoA substrate itself. |
| Cerivastatin sodium
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect. |
| 2-Hydroxy atorvastatin calcium salt
2-Hydroxy atorvastatin calcium salt is the hydroxyl metabolite of Atorvastatin calcium salt, an inhibitor of HMG-CoA reductase that inhibits cholesterol production with an IC50 value of 8 nM. |
| 4-Hydroxy atorvastatin calcium salt
4-Hydroxy atorvastatin calcium salt is the hydroxyl metabolite of Atorvastatin calcium salt, an inhibitor of HMG-CoA reductase that inhibits cholesterol production with an IC50 value of 8 nM. |
| Meglutol
Meglutol is an antilipidemic agent that lowers cholesterol, triglycerides, serum beta-lipoproteins, and phospholipids, and inhibits the activity of the rate-limiting enzyme of cholesterol biosynthesis, HMG-CoA reductase. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
